ALKS
Price
$41.22
Change
+$1.12 (+2.79%)
Updated
Oct 16 closing price
Capitalization
6.74B
11 days until earnings call
Intraday BUY SELL Signals
NBIX
Price
$135.71
Change
-$1.24 (-0.91%)
Updated
Oct 16 closing price
Capitalization
14.27B
16 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALKS vs NBIX

ALKS vs NBIX Comparison Chart in %
View a ticker or compare two or three
VS
ALKS vs. NBIX commentary
Oct 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and NBIX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALKS with price predictions
Oct 16, 2026

ALKS's RSI Oscillator ascends from oversold territory

The RSI Indicator for ALKS moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In 18 of the 21 cases the stock moved higher. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for ALKS just turned positive on October 05, 2026. Looking at past instances where ALKS's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.

Following a +5.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in 201 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ALKS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALKS as a result. In 65 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

The Aroon Indicator for ALKS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. ALKS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.724) is normal, around the industry mean (43.873). P/E Ratio (105.658) is within average values for comparable stocks, (141.710). ALKS's Projected Growth (PEG Ratio) (21.570) is very high in comparison to the industry average of (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.638) is also within normal values, averaging (178.797).

A.I.Advisor
a Summary for NBIX with price predictions
Oct 16, 2026

NBIX in +1.35% Uptrend, advancing for three consecutive days on October 15, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBIX advanced for three days, in 222 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Oscillator exited the oversold zone, 18 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In 48 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.

The Moving Average Convergence Divergence Histogram (MACD) for NBIX turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 31 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

The Aroon Indicator for NBIX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.865) is normal, around the industry mean (43.873). P/E Ratio (20.529) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. NBIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
ALKS vs NBIX: Fundamental Ratings
ALKS
NBIX
OUTLOOK RATING
1..100
8210
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
5262
SMR RATING
1..100
8544
PRICE GROWTH RATING
1..100
6061
P/E GROWTH RATING
1..100
291
SEASONALITY SCORE
1..100
113

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (57) in the Biotechnology industry is somewhat better than the same rating for ALKS (99). This means that NBIX’s stock grew somewhat faster than ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (52) in the Biotechnology industry is in the same range as NBIX (62). This means that ALKS’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for ALKS (85). This means that NBIX’s stock grew somewhat faster than ALKS’s over the last 12 months.

ALKS's Price Growth Rating (60) in the Biotechnology industry is in the same range as NBIX (61). This means that ALKS’s stock grew similarly to NBIX’s over the last 12 months.

ALKS's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for NBIX (91). This means that ALKS’s stock grew significantly faster than NBIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSNBIX
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
64%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
60%
Momentum
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 1 day ago
55%
MACD
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
58%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
56%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
56%
Advances
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 3 days ago
70%
Declines
ODDS (%)
Bearish Trend 4 days ago
65%
Bearish Trend 5 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
63%
Aroon
ODDS (%)
Bearish Trend 1 day ago
53%
Bearish Trend 1 day ago
52%
COMPARISON
Comparison
Oct 17, 2026
Stock price -- (ALKS: $41.22 vs. NBIX: $135.71)
Brand notoriety: ALKS and NBIX are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALKS: 198% vs. NBIX: 98%
Market capitalization -- ALKS: $6.74B vs. NBIX: $14.27B
ALKS [@Pharmaceuticals: Generic] is valued at $6.74B. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $14.27B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 1 FA rating(s) are green while NBIX’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 1 green, 4 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than ALKS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 5 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • ALKS’s TA Score: 5 bullish, 3 bearish.
  • NBIX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALKS is a better buy in the short-term than NBIX.

Price Growth

ALKS (@Pharmaceuticals: Generic) experienced а +1.50% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was -4.72% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -6.95%. For the same industry, the average monthly price growth was -5.23%, and the average quarterly price growth was +10.96%.

Reported Earning Dates

ALKS is expected to report earnings on Oct 28, 2026.

NBIX is expected to report earnings on Nov 02, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-6.95% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
ALKS
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TLPH1.080.01
+0.93%
Talphera
ONBPP25.000.12
+0.48%
Old National Bancorp
ZD57.15-1.29
-2.21%
Ziff Davis
FBYD8.32-0.20
-2.35%
Falcon's Beyond Global Inc
CAI30.56-1.20
-3.78%
Caris Life Sciences Inc

ALKS and

Correlation & Price change

A.I.dvisor tells us that ALKS and NBIX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALKS and NBIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
+2.79%
NBIX - ALKS
31%
Poorly correlated
-0.91%
VTRS - ALKS
30%
Poorly correlated
+2.39%
ACET - ALKS
30%
Poorly correlated
-11.09%
AMRX - ALKS
27%
Poorly correlated
-0.36%
LQDA - ALKS
25%
Poorly correlated
-1.24%
More

NBIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with BIOA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then BIOA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-0.91%
BIOA - NBIX
37%
Loosely correlated
-9.53%
ALKS - NBIX
32%
Poorly correlated
+2.79%
AKBA - NBIX
32%
Poorly correlated
-3.67%
KNSA - NBIX
28%
Poorly correlated
-1.69%
BCRX - NBIX
26%
Poorly correlated
-2.87%
More